Business
Ypsomed : Presentation of Full-Year Results 2025/26
Ypsomed : Presentation of Full-Year Results
About this update from Ypsomed Holding Ag
[{"type":"text","content":" Ypsomed Full Year Results 2025/26 Transforming selfcare, Transforming Ypsomed Zurich, 20 May 2026 Important information The information contained in this document has not been verified by an independent source. It should be taken with caution, and no assurance or guarantee is given (either explicit or implied) regarding the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG nor advisors or affiliates of Ypsomed Holding AG shall be liable in any way for losses occurred in conjunction with the use of this document, its contents or any other connection with this document. This document is neither an offer (or part of an offer) for the sale, nor a solicitation for the purchase of shares, and neither the document nor parts thereof form the basis of any contract or otherwise obligation. This document contains future-oriented statements which include uncertainties and risks. Such statements are indicated by such words as \"could\", \"planned\", \"expected\", \"believed\" and similar expressions or their context. These statements are made based on current knowledge and current assumptions. Due to a variety of different factors, the actual future results, developments or events may deviate considerably from those mentioned here. There is no obligation whatsoever to update future-oriented statements. Making selfcare simpler and easier We benefit from multiple structural growth drivers Selfcare Move from IV to subcutaneous delivery to enhance quality of life, encouraging therapy adherence and lower healthcare cost Biologics Next generation drugs are mostly large molecules that must be injected Biosimilars Expanding access to affordable medical care worldwide Incretins Transforming healthcare and society, improving public health, productivity, and quality of life for millions Ypsomed has completed its transformational journey to become a pure-play self-injection specialist Ypsomed is now a pure-play self-injection specialist 2026 2025 2025 2024 2023 2022 Phase-out of contract manufacturing delivery systems Completion of the sale of Ypsotec Completion of the sale of the diabetes care business Completion of the sale of the pen needle and blood glucose monitoring business Completion of the sale of the DiaExpert retail business in Germany Transformation from matrix struct...